Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB) -- Ignore unavailable to you. Want to Upgrade?

To: William Marsh who wrote (99)	10/21/1999 5:19:00 PM
From: Heat Shock	Read Replies (1) \| Respond to of 236

William, I agree with your remarks. One nice thing about the Genzyme acquisition of Cell Genesys is that GZMO will acquire new gene delivery vectors. This raises the possibility, however faint, that the back burner stress protein gene therapy could be tried with some of these new vectors. This would pertain if the stress protein gene therapy "equivocal results" were due to the vector. The CELG web site says they have retroviral vectors, adenoviral vectors, adeno-associated viral vectors and lentiviral vectors. Heat